ESMO 2014 Congress

IFEMA – Feria de Madrid, Madrid, Spain, 26-30 September 2014

ESMO Press Conference Room

PRESS CONFERENCE PROGRAMME

Opening press conference

Friday, 26 September, 11:00-11:45

Moderator: Solange Peters, ESMO 2014 Press Officer

Speakers: Rolf Stahel, ESMO President; Johann de Bono, ESMO 2014 Scientific Chair; Susana Banerjee, Royal Marsden Hospital NHS Foundation Trust, UK

ESMO's President welcome	Rolf Stahel, Universitätsspital Zürich, Zürich, Switzerland
Congress figures and programme highlights	Johann de Bono, Royal Marsden Hospital and The Institute of Cancer Research, London, United Kingdom
How fast can cancer drugs reach patients?	
Professional burnout in European Young Oncologists: a serious risk for doctors and patients alike?	Susana Banerjee, Royal Marsden Hospital NHS Foundation Trust, London, UK
Appointment for journalists	Solange Peters, Centre Hospitalier Universitaire Vaudois (CHUV), Centre Pluridisciplinaire d'Oncologie, Lausanne, Switzerland

The discussion on the process to approve anti-cancer drugs in various countries will refer to the following studies:

1036O Cross-comparison of cancer drug approvals among international regulatory bodies	N.Samuel, Sunnybrook Health Sciences Centre, Toronto, Canada
1387PD Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA	Felipe Ades Moraes, Institut Jules Bordet, Brussels, Belgium

The discussion on the risk of burnout will refer to the following study:

1081O Professional burnout in European young oncologists:a european survey conducted by the European Society for Medical Oncology (ESMO) Committee	S. Banerjee, Department Of Medicine, Royal Marsden Hospital NHS Foundation Trust, London, UK

Data presented at this Press Conference is embargoed until Friday, 26 September 2014 at 12:00 CEST

Press briefing 1

Saturday, 27 September 2014, 8:15-9:00 (CEST)

Moderator: Giuseppe Curigliano, European Institute of Oncology (IEO), Milan, Italy

Programme
The data presented will refer to the following studies:

267PD Cancer during pregnancy: A case-control analysis of mental development and cardiac functioning of 38 children prenatally exposed to chemotherapy	Frédéric Amant, University of Leuven, Leuven, Belgium
LBA29 Afatinib versus methotrexate (MTX) as second-line treatment for patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) who progressed after platinum-based therapy: primary efficacy results of LUX-head & neck 1, a phase III trial	Jean-Pascal Machiels, Cliniques Universitaires St. Luc, Brussels, Belgium
1483O Anamorelin for the treatment of cancer anorexia-cachexia in NSCLC: results from the Phase 3 studies ROMANA 1 and 2	David Currow, Flinders University, Adelaide, Australia
LBA47 Phase 3 (P04832) trial results for rolapitant, a novel NK-1 receptor antagonist, in the prevention of chemotherapy-induced nausea and vomiting (CINV) in subjects receiving cisplatin-based chemotherapy	Bernardo Leon Rapoport, The Medical Oncology Centre – Rosebank, Johannesburg, South Africa

Data presented at this Press Conference is embargoed until Saturday, 27 September 2014 at 9:00 CEST

Press Conference

Saturday, 27 September 2014, 12:15-13:00 (CEST)

The methodology of clinical trials in rare tumours

Moderator: Jean-Yves Blay, Centre Leon Berard, Université Claude Bernard, Lyon, France

Speakers: Paolo G. Casali, Istituto Nazionale Tumori, Milan, Italy; *others to be confirmed*

Programme

During this press conference, journalists will be presented with the Rare Cancers Europe methodological recommendations for clinical studies in rare cancers, a multi-stakeholder position paper calling for different criteria to be used in clinical trials for rare cancer treatments.

How to address the challenges of taking clinical decisions in rare cancers	Paolo G. Casali, Istituto Nazionale Tumori, Milan, Italy
How to address challenges in designing clinical trials in rare cancers	Vassilis Gonfinopoulos, EORTC
How to address the challenges in rare cancer patients referral	Markus Wartenberg, SPAEN

The RCE Position Paper presented during this press conference will be embargoed until Thursday, 2 October 2014, 2:05 CEST.

Press briefing 2

Sunday, 28 September 2014, 8:15-9:00 (CEST)

Moderator: Eric Van Cutsem, University of Leuven, Leuven, Belgium

Programme
The data presented will refer to the following studies:

LBA2 Gefitinib/chemotherapy vs chemotherapy in epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) after progression on first-line gefitinib: the Phase III, randomised IMPRESS study	Tony Mok, The Chinese University of Hong Kong, Shatin, China
350O Final overall survival (OS) analysis from the CLEOPATRA study of first-line (1L) pertuzumab (Ptz), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC)	Sandra Swain, Washington Cancer Institute, Washington, United States
1173O MAGRIT, a double-blind, randomized, placebo-controlled Phase III study to assess the efficacy of the recMAGE-A3 + AS15 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small cell lung cancer (NSCLC)	Johan F. Vansteenkiste, University Hospitals Leuven - Campus Gasthuisberg, Leuven, Belgium
LBA25 CIRCCa: A randomised double blind phase II trial of carboplatin-paclitaxel plus cediranib versus carboplatin-paclitaxel plus placebo in metastatic/recurrent cervical cancer. (CRUK Grant Ref: C1256/A11416)	Raymond Symonds, University Hospitals of Leicester NHS Trust Leicester Royal Infirmary, Leicester, United Kingdom

Data presented at this Press Conference is embargoed until Sunday, 28 September 2014 at 9:00 CEST

Educational session for journalists

Sunday, 28 September 2014, 14:00-15:00 (CEST)

RAS Testing in Colorectal Cancer Patients: How to Define an Optimal Treatment Strategy

Moderator: Dirk Arnold, Klinik für Tumorbiologie Albert Ludwigs University, Freiburg, Germany

Speakers: Eric Van Cutsem, University of Leuven, Leuven, Belgium; Fortunato Ciardiello, Seconda Università di Napoli, Naples, Italy; Heinz-Josef Lenz, University of Southern California Norris Comprehensive Cancer Center, USA; Alan Venook, University of California, USA

Programme

This session will offer members of the press important insight on the use of RAS testing in colorectal cancer patients, helping them find their way through the multitude of latest research results on one of the Big Killers worldwide:

- What is RAS testing?
- What does RAS testing offer to clinicians?
- How promising is RAS testing for cancer care?

The discussion will be supported by the presentation of the following studies:

501O CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leuvocorin (MFOLFOX6) with bevacizumab (bv) or cetuximab (cet) for patients (pts) with expanded RAS analysis untreated metastatic adenocarcinoma of the colon or rectum (MCRC)	Heinz-Josef Lenz, University of Southern California Norris Comprehensive Cancer Center, USA
LBA10 CALGB/SWOG 80405: analysis of patients undergoing surgery as part of treatment strategy	Alan Venook, University of California, USA

Data presented at this Press Event is embargoed until Monday, 29 September 2014 at 12:45 CEST

Press briefing 3

Monday, 29 September 2014, 8:15-9:00 (CEST)

Moderator: Evandro de Azambuja, Institut Jules Bordet, Brussels, Belgium

Programme
The data presented will refer to the following studies:

LBA3 A phase 3 randomized, open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator's choice chemotherapy (ICC) in patients with advanced melanoma after prior anti-CTLA-4 therapy	Jeffrey Weber, H. Lee Moffitt Cancer Center & Research Institute, Tampa, United States
LBA5 Phase 3, Double-Blind, Placebo-Controlled Study of Vemurafenib Versus Vemurafenib + Cobimetinib in Previously Untreated BRAFV600 Mutation–Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma (NCT01689519)	Grant McArthur, Peter MacCallum Cancer Centre, Melbourne, Australia
LBA4 COMBI-v: A randomised, open-label, Phase III study comparing the combination of dabrafenib and trametinib to vemurafenib as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma	Caroline Robert, Gustave Roussy, Villejuif, France
LBA37 Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma (MPM) with or without hemithoracic radiotherapy: final results of the randomized multicenter phase II trial SAKK17/04	Rolf Stahel, Universitätsspital Zürich, Zürich, Switzerland

Data presented at this Press Conference is embargoed until Monday, 29 September 2014 at 9:00 CEST

ESMO Congress reality check: What does it mean for patients?

Monday, 29 September 2014, 16:30-18:00 (CEST)

Moderator: Franco Cavalli, European School of Oncology (ESO) Scientific Chair, Milan, Italy

Speakers: Cora Sternberg, Head of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy; Marek Kania, VP Medical Affairs Lilly Oncology, Jan Geissler, Chronic Myeloid Leukaemia; José Martin Moreno, former Director General of Public Health & Chief Medical Officer of Spain

Programme
An interactive event to help journalists report on the quality of cancer care

Within the framework of an ESO-initiated training in collaboration with the European Society for Medical Oncology, journalists will have the chance to quiz representatives from the industry, health policy, medical oncology and patient advocacy about the reality of patient access to state-of-the-art cancer care in Europe's overstretched healthcare systems.

Speakers will be given 10 minutes each for an initial presentation, leaving more than one hour for questions and discussion.

This is not a press conference: video and audio recording will not be allowed.

Closing press conference

Tuesday, 30 September, 8:15-9:00

Moderator: Solange Peters, ESMO 2014 Press Officer

Speakers: Johann de Bono, ESMO 2014 Scientific Chair; Fortunato Ciardiello, ESMO President Elect; *others to be confirmed*

Top practice changes to implement after ESMO 2014	Johann de Bono, Royal Marsden Hospital and The Institute of Cancer Research, United Kingdom
The paradigm of precision medicine: reality or dream?	Johann de Bono, Royal Marsden Hospital and The Institute of Cancer Research, United Kingdom
What's in the pipeline?	TBC
The future of ESMO	Fortunato Ciardiello, Seconda Università di Napoli, Naples, Italy
Congress figures and take-home messages	Solange Peters, Centre Hospitalier Universitaire Vaudois (CHUV), Centre Pluridisciplinaire d'Oncologie, Switzerland